#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Prevalence and Incidence of Age-Related Macular Degeneration in Europe – Current Overview and Trend Analysis

A comprehensive review article by authors from Bonn, Germany, published late last year in the British Journal of Ophthalmology, provides current data and estimates of the incidence and prevalence of age-related macular degeneration in Europe. Here is a brief summary of the key findings from this latest analysis.
Source: Glaucoma 6. 2. 2020

News What can we base the decision on for the choice of initial treatment modality for CLL?

We now have a range of highly effective treatment options for patients with chronic lymphocytic leukemia (CLL). New drugs have significantly contributed to improved overall survival (OS). However, there are still questions about the most appropriate treatment regimen or criteria for choosing the initial therapeutic modality. Some of these questions are posed—and answers sought—by Professor John F. Seymour from the University of Melbourne in his recent communication.
Source: Chronic Lymphocytic Leukemia 18. 5. 2022

News What situations can arise in PBC treatment with obeticholic acid? Answers provided by case studies from real practice at CKTCH

The Hradec Gastroenterology Days 2023 were traditionally held in March at the Educational Center of the Faculty of Medicine, Charles University, in the area of University Hospital Hradec Králové. The expert program included a lecture by MUDr. Libuše Husová, Ph.D., from the Cardio-surgical and Transplant Surgery Center Brno (CKTCH), who highlighted various situations that can arise during the treatment of primary biliary cholangitis (PBC) with three case studies.
Source: Primary Biliary Cholangitis 25. 4. 2023

News Is the Quality of Life for Patients with Atrial Fibrillation and Heart Failure Comparable When Treated with Bisoprolol and Digoxin?

The British RATE-AF study, published in December 2020 in the JAMA journal, compared the impact on improving the quality of life in patients with permanent atrial fibrillation (AF) and symptoms of heart failure when administering bisoprolol and low-dose digoxin.
Source: Cardiovascular Continuum 21. 9. 2021

News Meta-analysis of the Metabolic Effects of Second-generation Antipsychotics

Second-generation antipsychotics used in the therapy of schizophrenia exhibit varying metabolic profiles. A recently conducted meta-analysis by Italian authors investigated the impact of second-generation antipsychotics on weight gain, BMI, lipid spectrum, and glycemia.
Source: Modern Treatment of Schizophrenia 1. 11. 2022

News Administration of Fibrinogen Concentrate in Patients with Persistent Bleeding After Cardiac Surgery

Is the administration of fibrinogen concentrate in patients with persistent bleeding after initial cardiac surgery associated with an increased risk of thromboembolic events or death? Authors of a Swedish observational study published last year aimed to answer this question.
Source: Life-threatening Bleeding 20. 5. 2022

News Quality of Life of Patients on Adjuvant Treatment for HER2-Positive Breast Cancer

The KATHERINE clinical trial demonstrated that adjuvant therapy with trastuzumab emtansine compared to trastuzumab significantly improves invasive disease-free survival in patients with HER2-positive early breast cancer and residual invasive disease after prior treatment. A post hoc analysis of this study was published in the journal Cancer, focusing on patient-reported outcomes related to quality of life during and after treatment.
Source: Breast Carcinoma 28. 5. 2020

News Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice

A recent survey among German-speaking physicians evaluated the use of non-opioid analgesics in perioperative care in children under 14 years. It focused on the use of metamizole and the monitoring of possible agranulocytosis associated with this drug.
Source: Analgesia 17. 3. 2020

News Lung screening in the Czech Republic has detected over a hundred cases of lung cancer

The purpose of lung screening, which has been ongoing in the Czech Republic since January 2022, is to detect early stages of lung cancer and increase awareness of this malignant disease in relation to smoking. Data analysis from health insurance companies through the National Registry of Paid Health Services (NRHZS) revealed that out of nearly 4,000 individuals who underwent low-dose CT as part of the screening examination, 116 were diagnosed with cancer.
Source: Respiratory Health 7. 12. 2023

News Clinical and Microbiological Effect of L. reuteri in the Treatment of Chronic Periodontitis

The Journal of Clinical Periodontology published the results of a study evaluating the effect of the probiotic bacterial strain Lactobacillus reuteri as an adjunctive treatment for chronic periodontitis.
Source: GI, colic and microbiome 6. 4. 2022

News Facilitated Immunoglobulin Substitution Therapy in Paediatric Patients with Immunodeficiency – Real-World Data

Patients with humoral immunodeficiency are indicated for immunoglobulin substitution therapy. The study presented below summarizes real-world data concerning the latest substitution method (i.e., facilitated subcutaneous administration) in paediatric patients.
Source: Primary and Secondary Immunodeficiencies 16. 10. 2023

News Young man with nephrotic syndrome and portal vein thrombus successfully treated with edoxaban − case report

Venous thrombosis is one of the main complications of nephrotic syndrome (NS), though it is most often located in the renal vein. The following case report describes an adult patient with relapsing corticosteroid-dependent minimal change disease complicated by portal vein thrombosis and subsequent successful treatment with edoxaban.
Source: Atrial Fibrillation 26. 3. 2020

News Experiences with Long-term Treatment of Psoriasis with Interleukin 17A Inhibitor

The current publication of the long-term extension of the UNCOVER-3 study, which focused on the treatment of psoriasis with ixekizumab, describes the efficacy and safety of 4 years of use of this drug.
Source: Biological Treatment 13. 4. 2021

News News in the Treatment of Allergic Rhinitis

According to literary sources, 17–28.5% of Europeans suffer from allergic rhinitis (AR), which negatively affects the quality of daily life. Below, we summarize the new recommendations from ARIA (Allergic Rhinitis and its Impact on Asthma) from 2019 regarding the treatment of this condition and highlight a new therapeutic option offered by the fixed combination of mometasone furoate with olopatadine hydrochloride.
Source: Life Without Allergic Rhinitis 27. 4. 2022

News When Size Matters or What Is Small Is Effective

The systemic effect of an orally administered drug can be expected, among other things, if it has suitable physicochemical properties. How can insufficient absorption or poor solubility be solved? We provide the answer below.
Source: Venous Insufficiency 28. 5. 2020

News Neuraxpharm Introduces a New Form of Medical Cannabis

Since November 2022, a new medication containing an active full-spectrum cannabis extract – Naxiva Panaxol from Neuraxpharm – has been available in the Czech Republic. The cannabis extract is offered in collaboration with Panaxia Labs Israel. Both companies are key players in the European medical cannabis market. Their agreement ensures the distribution of these products not only in the Czech Republic but also in Switzerland and Germany.
Source: Medical Cannabis 16. 3. 2023

News Insufficient dosing of enoxaparin is common in patients post-orthopedic surgery and increases the risk of thromboembolic disease

Orthopedic and traumatological procedures involving the pelvis and lower limbs are associated with a significant increase in the risk of thromboembolic disease. Therefore, prophylaxis with anticoagulants is recommended in the perioperative and postoperative period for these procedures. The most commonly administered anticoagulants are low molecular weight heparins, among which enoxaparin is included. A recently published study by authors from the University of Utah focused on insufficient dosing of enoxaparin and its impact on the development of thromboembolic disease within 90 days following the procedure.
Source: Thromboprophylaxis 17. 3. 2020

News INFOGRAPHIC: Eye Drops for Dry and Irritated Eyes – Mechanism of Action and Benefits

Source: Ophthalmologic Diseases 2. 5. 2023

News Presence of Risk Factors Associated with Colectomy in Patients with Ulcerative Colitis in Studies with Tofacitinib

One of the important goals of active ulcerative colitis therapy is the prevention of colectomy. A clinical study, the results of which were recently presented at the Vienna UEG (United European Gastroenterology) congress, evaluated the association of risk factors and the use of tofacitinib with colectomy in patients with active ulcerative colitis in the OCTAVE clinical trial program.
Source: Intestinal Inflammations 4. 12. 2022

News Need for Early Intervention in COPD − A Suitable Time for Mucolytic Treatment

Chronic Obstructive Pulmonary Disease (COPD) ranks third among the leading causes of morbidity and mortality worldwide, with more than 210 million people expected to be affected by 2030. While common, it is preventable and treatable. The mucolytic erdosteine has proven to be an effective helper in COPD therapy.
Source: Cough Therapy 24. 5. 2022

News Trifluridine/tipiracil in Real Clinical Practice – Current Data from Spain

Trifluridine/tipiracil is indicated for the treatment of patients with refractory metastatic colorectal cancer (mCRC), where clinical studies have shown it extends overall survival (OS) and progression-free survival (PFS). At this year's virtual World Congress on Gastrointestinal Cancer of the European Society for Clinical Oncology (ESMO), held from June 30, a Spanish study on the efficacy of trifluridine/tipiracil in real-world clinical practice was presented.
Source: Treatment of Gastrointestinal Carcinomas 9. 9. 2021

News Efficacy and Safety of Fenfluramine in the Treatment of Lennox-Gastaut Syndrome – An Overview of Current Knowledge

In a recently published article, British authors summarize the current knowledge on the efficacy and safety of fenfluramine (FFA) in the treatment of Lennox-Gastaut syndrome (LGS, a developmental and epileptic encephalopathy). In addition to the reduction in seizure frequency demonstrated in clinical studies, they discuss the impact of fenfluramine on reducing the risk of sudden unexpected death in epilepsy (SUDEP), improving cognitive function in patients, and its safety concerning weight loss and heart disorders.
Source: Rare Diseases in Neurology 21. 6. 2024

News Is exposure to mite allergens in breast milk or house dust a risk factor for asthma and allergies in childhood?

Exposure to mite allergens occurs early in life from both breast milk and house dust (especially bedding). The study presented below examined the impact of exposure to the dominant mite allergen Der p 1 on serum immunoglobulin E (IgE) levels and the development of bronchial asthma in childhood.
Source: Dust Mite Allergy 23. 2. 2023

News Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction

Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetics and non-diabetics. The aim of the EMPEROR-Preserved clinical trial was to supplement data on the efficacy and safety of empagliflozin in a population of patients with heart failure with preserved ejection fraction (HFpEF; EF LK > 40%).
Source: Heart Failure 27. 4. 2022

News What is new in the treatment of atopic dermatitis and how are comorbidities affecting it?

Allergic rhinitis, conjunctivitis, bronchial asthma, or autoimmune diseases like alopecia, vitiligo, celiac disease, and idiopathic inflammatory bowel diseases – these are comorbidities that often trouble patients with atopic dermatitis (AD). Modern systemic treatments bring new hope to these patients. "The primary benefit of targeted treatment, especially for severe AD, is the mitigation or elimination of chronic inflammation and persistent itching, significantly improving the quality of life for patients," says Chief Physician MUDr. Miroslav Nečas, Ph.D., from the 1st Department of Dermatovenereology of MU and St. Anne's University Hospital in Brno.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 26. 6. 2023

1 27 28 29 30 31 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#